TANJU KETEN, ÜNSAL EROĞLU, MELİH BALCI, ŞEREF COŞER, HALİL DEMİRÇAKAN, SERDAR BAŞBOĞA, ALİ YASİN ÖZERCAN, BURAK KÖSEOĞLU, ÖZER GÜZEL, ALTUĞ TUNCEL
Comprehensive Medicine - 2023;15(3):194-198
INTRODUCTION: Iliopsoas hematoma (IPH) is a potential life-threatening condition that generally appears after trauma and concomitant hematologic abnormalities. It may rarely occur spontaneously. We determined a significant increase in the prevalence of this rarely encountered entity during the COVID-19 pandemic. Therefore, in this study, we aimed to investigate the relationship between COVID-19 and IPH. METHODS: The study included 18 patients who were hospitalized in our hospital due to COVID-19 between February 2020 and February 2021 and were consulted to our clinic due to the detection of IPH in abdominal computed tomography (CT) during their follow-up. Demographic data, medical history, physical examination findings, laboratory tests, and radiological imaging results of the patients and administered anticoagulant and antiaggregants were recorded. Results: The median age was 63±13.6 (4290) years. Eleven (61.1%) patients were consulted from the COVID-19 intensive care units and 7 (38.9%) were consulted from the COVID-19 wards. All patients were on anticoagulants at the time of IPH diagnosis. Eight (44.4%) patients had already been on anticoagulants before they had COVID-19. The largest diameter of hematoma measured by CT varied between 4 and 15 cm in the axial plane and 912 cm in the coronal plane. Seven patients (38.9%) died on days 111 after IPH diagnosis. DISCUSSION AND CONCLUSION: Given the indications for prescribing anticoagulant therapy in COVID-19 and the lack of definite evidence regarding its optimal dose and duration, it is important to be aware of IPH as a potentially severe complication in hospitalized COVID-19 patients.
